• Juva Life Inc. has received state approval for its cannabis cultivation facility
  • The plant is located in Stockton, California, encompassing almost 30-thousand square feet
  • The company is moving to plant 8,000 sq. ft. of flowering canopy and 5,000 sq. ft. of non-flowering canopy
  • Once fully-operational, the facility is expected to have the capability to produce approximately 6,000 lbs. of cannabis annually
  • Shares of Juva Life are up 6.13 per cent to C$1.73

The State of California has given the green light to Juva Life Inc. (JUVA) for its cannabis production facility.

The company is now moving swiftly to fully-activate the almost 30-thousand-square-foot plant in Stockton.

Three of the five growing spaces are ready for immediate planting with another two expected to be completed by the second quarter of 2021.

The company is planting approximately 8,000 square feet of flowering canopy and 5,000 square feet of non-flowering canopy.

An additional 4,500 square feet of space has been subdivided into trim, dry storage, breeding, pre-roll, packaging, and environmental system rooms.

Once the facility is fully-operational, it is expected to have an annual capability of producing approximately 6,000-pounds of cannabis flower.

Cultivated flower production is slated for use in Juva branded products, contract production services, and clinical research targeting novel product formulations.

The company has been operating a cannabis delivery fleet from the location since October, 2020.

Juva founder and CEO Doug Chloupek called this a milestone for the company.

“Now that we can commence cultivation, we are firmly in charge of our destiny. We can control product quality and output in order to service our growing enterprise, as well as generate quantifiable returns,” Chloupek said.

Shares of Juva Life are up 6.13 per cent to C$1.73 at 2:40 EST.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.